Abeona Therapeutics Inc. (ABEO) EPS Estimated At $-0.16; Shorts at OUTOTEC OYJ ORDINARY SHARES FINLAND (OUKPF) Lowered By 48.52%

July 27, 2018 - By Tyler Harlow

Outotec Oyj (OTCMKTS:OUKPF) Logo

Analysts expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report $-0.16 EPS on August, 21.They anticipate $0.05 EPS change or 23.81% from last quarter’s $-0.21 EPS. After having $-0.18 EPS previously, Abeona Therapeutics Inc.’s analysts see -11.11% EPS growth. The stock increased 0.77% or $0.1 during the last trading session, reaching $13.1. About 316,625 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 191.23% since July 27, 2017 and is uptrending. It has outperformed by 178.66% the S&P500. Some Historical ABEO News: 18/05/2018 – Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting; 20/04/2018 – Abeona Therapeutics Receives EU Orphan Drug Designation for ABO-202 Gene Therapy Program in Batten Disease; 14/05/2018 – Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors; 16/03/2018 – ABEONA THERAPEUTICS WITHDRAWS S-1; 18/05/2018 – ABEONA THERAPEUTICS INC – ABO-102 IS WELL-TOLERATED IN ALL SUBJECTS TO DATE, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED; 15/03/2018 – ABEO GETS FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202; 17/05/2018 – ABEO: TRIAL MET SAFETY, TOLERABILITY, PRELIM EFFICACY ENDPOINTS; 11/05/2018 – ABEONA THERAPEUTICS INC – CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018 WERE $132 MLN, COMPARED TO $137.8 MLN AS OF DECEMBER 31, 2017; 18/05/2018 – ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS lllA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING; 16/03/2018 – ABEONA THERAPEUTICS WITHDRAWS FORM S-1

OUTOTEC OYJ ORDINARY SHARES FINLAND (OTCMKTS:OUKPF) had a decrease of 48.52% in short interest. OUKPF’s SI was 125,500 shares in July as released by FINRA. Its down 48.52% from 243,800 shares previously. The SI to OUTOTEC OYJ ORDINARY SHARES FINLAND’s float is 0.08%. The stock increased 6.91% or $0.56 during the last trading session, reaching $8.66. About 1,000 shares traded or Infinity% up from the average. Outotec Oyj (OTCMKTS:OUKPF) has 0.00% since July 27, 2017 and is . It has underperformed by 12.57% the S&P500.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $619.70 million. The company's lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More news for Abeona Therapeutics Inc. (NASDAQ:ABEO) were recently published by: Digitaljournal.com, which released: “NASDAQ: ABEO Shareholder Notice: Investigation over Potential Wrongdoing at Abeona Therapeutics Inc” on July 20, 2018. Gurufocus.com‘s article titled: “Andreas Halvorsen Takes Stake in Eidos Therapeutics” and published on July 03, 2018 is yet another important article.

Among 5 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 17 analyst reports since January 29, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, February 8 by H.C. Wainwright. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Monday, May 14 by H.C. Wainwright. The firm has “Buy” rating given on Monday, April 2 by H.C. Wainwright. Cantor Fitzgerald maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Tuesday, March 20 with “Buy” rating. The company was maintained on Friday, April 20 by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald on Tuesday, May 15 with “Buy”. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Tuesday, June 5 by H.C. Wainwright. The rating was initiated by Seaport Global on Tuesday, June 5 with “Buy”. The firm has “Buy” rating given on Thursday, April 12 by H.C. Wainwright. The stock has “Buy” rating by Cantor Fitzgerald on Monday, January 29.

Outotec Oyj provides process solutions, technologies, and services for the mining and metallurgical industries in Europe, Africa, Asia, North and South America, and Australia. The company has market cap of $1.59 billion. It operates through two divisions, Minerals Processing; and Metals, Energy & Water. It currently has negative earnings. The Minerals Processing segment offers mineral processing solutions, including pre-feasibility studies, and complete plants and life cycle services to mining industry.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts